Recruiting for clinical trial in pregnancies at risk for Hemolytic Disease of the Fetus and Newborn (HDFN)


Dr. John Smoleniec is the principal investigator for the efficacy and safety of nipocalimab in pregnancies at risk for severe haemolytic disease of the foetus and newborn (HDFN) clinical research study (Azalea) at Liverpool Hospital (Sydney, Australia). the study is seeking referrals for eligible patient who is pregnant or has plans to become pregnant again who may be interested in participating in a clinical trial to treat HDFN.

A brief participation criteria and further information regarding this clinical trial can be found on clinicaltrials.gov.

Dr. Smoleniec will assess eligibility further using a complete eligibility criteria.

To refer patients, or for more information about this study, please email the Principal Investigator Dr. John Smoleniec on: john.smoleniec@health.nsw.gov.au, and CC the study coordinator Marie-Elle Ajaka: marieelle.ajaka@health.nsw.gov.au.

The flyer can be found here.

Share Recruiting for clinical trial in pregnancies at risk for Hemolytic Disease of the Fetus and Newborn (HDFN) on Facebook Share Recruiting for clinical trial in pregnancies at risk for Hemolytic Disease of the Fetus and Newborn (HDFN) on Twitter Share Recruiting for clinical trial in pregnancies at risk for Hemolytic Disease of the Fetus and Newborn (HDFN) on Linkedin Email Recruiting for clinical trial in pregnancies at risk for Hemolytic Disease of the Fetus and Newborn (HDFN) link